# A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines

> **NCT05933512** · PHASE2 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 600 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** SCTV01E-2
- **BIOLOGICAL:** SCTV01E

## Key facts

- **NCT ID:** NCT05933512
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-10
- **Primary completion:** 2023-12-10
- **Final completion:** 2024-11-10
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933512, "A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05933512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*